Income Statement

Currency: USD

	Dec-2021	Mar-2022	Jun-2022	Sep-2022	Dec-2022	Mar-2023	Jun-2023	Sep-2023	Dec-2023	Mar-2024	Jun-2024	Sep-2024	Dec-2024	Mar-2025	Jun-2025	Sep-2025
Revenue
Revenue	0 N/A	0 N/A	0 N/A	0 N/A	0 N/A	25 N/A	43 +72%	87 +101%	129 +48%	163 +26%	239 +47%	215 -10%	211 -2%	172 -18%	79 -54%	62 -23%
Operating Income
Operating Expenses	(51)	(55)	(79)	(90)	(97)	(106)	(117)	(121)	(132)	(139)	(146)	(157)	(164)	(167)	(175)	(183)
Selling, General & Administrative	(15)	(16)	(24)	(27)	(31)	(32)	(33)	(34)	(32)	(34)	(35)	(37)	(38)	(39)	(41)	(41)
Research & Development	(36)	(39)	(55)	(63)	(67)	(74)	(84)	(87)	(100)	(105)	(111)	(120)	(125)	(129)	(135)	(142)
Operating Income	(51) N/A	(55) -8%	(79) -43%	(90) -15%	(97) -8%	(81) +17%	(74) +9%	(34) +54%	(3) +91%	24 N/A	93 +292%	57 -39%	47 -18%	3 -93%	(97) N/A	(122) -26%
Pre-Tax Income
Interest Income Expense	(0)	0	1	2	3	5	9	12	15	17	17	19	19	20	19	17
Pre-Tax Income	(51) N/A	(55) -7%	(78) -42%	(88) -14%	(95) -7%	(76) +20%	(65) +15%	(22) +66%	12 N/A	41 +236%	111 +173%	77 -31%	66 -13%	24 -64%	(77) N/A	(104) -36%
Net Income
Tax Provision	0	0	0	0	0	(4)	(17)	0	(19)	(17)	(6)	(21)	(1)	1	4	1
Income from Continuing Operations	(51)	(55)	(78)	(88)	(95)	(80)	(82)	(22)	(7)	23	104	55	66	25	(73)	(103)
Net Income (Common)	(51) N/A	(55) -7%	(78) -42%	(88) -14%	(95) -7%	(80) +16%	(82) -3%	(22) +74%	(7) +69%	23 N/A	104 +345%	55 -47%	66 +19%	25 -62%	(73) N/A	(103) -41%
EPS (Diluted)	-8.16 N/A	-1.74 +79%	-2.48 -43%	-2.82 -14%	-3.02 -7%	-2.45 +19%	-2.48 -1%	-0.62 +75%	-0.2 +68%	0.67 N/A	2.9 +333%	1.34 -54%	1.68 +25%	0.6 -64%	-1.79 N/A	-2.5 -40%

Entrada Therapeutics Inc
NASDAQ:TRDA